EP3633037A4 - Acides nucléiques suppresseurs de l'expression d'apcs - Google Patents

Acides nucléiques suppresseurs de l'expression d'apcs Download PDF

Info

Publication number
EP3633037A4
EP3633037A4 EP18810658.7A EP18810658A EP3633037A4 EP 3633037 A4 EP3633037 A4 EP 3633037A4 EP 18810658 A EP18810658 A EP 18810658A EP 3633037 A4 EP3633037 A4 EP 3633037A4
Authority
EP
European Patent Office
Prior art keywords
apcs
expression
nucleic acids
suppressing nucleic
suppressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18810658.7A
Other languages
German (de)
English (en)
Other versions
EP3633037A1 (fr
Inventor
Hiroyuki ARIYAMA
Takuya Murakami
Takashi Imaeda
Tatsuya Miyazawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co Ltd filed Critical Kyowa Kirin Co Ltd
Publication of EP3633037A1 publication Critical patent/EP3633037A1/fr
Publication of EP3633037A4 publication Critical patent/EP3633037A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP18810658.7A 2017-05-31 2018-05-31 Acides nucléiques suppresseurs de l'expression d'apcs Withdrawn EP3633037A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017108502 2017-05-31
PCT/JP2018/020941 WO2018221649A1 (fr) 2017-05-31 2018-05-31 Acides nucléiques suppresseurs de l'expression d'apcs

Publications (2)

Publication Number Publication Date
EP3633037A1 EP3633037A1 (fr) 2020-04-08
EP3633037A4 true EP3633037A4 (fr) 2021-03-24

Family

ID=64456286

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18810658.7A Withdrawn EP3633037A4 (fr) 2017-05-31 2018-05-31 Acides nucléiques suppresseurs de l'expression d'apcs

Country Status (9)

Country Link
US (1) US11466272B2 (fr)
EP (1) EP3633037A4 (fr)
JP (1) JPWO2018221649A1 (fr)
KR (1) KR20200014320A (fr)
CN (1) CN110832078A (fr)
AU (1) AU2018277476A1 (fr)
CA (1) CA3065149A1 (fr)
TW (1) TW201903149A (fr)
WO (1) WO2018221649A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019100039A1 (fr) * 2017-11-20 2019-05-23 Alnylam Pharmaceuticals, Inc. Compositions d'arni de composant p amyloïde serique et leurs procédés d'utilisation
JPWO2020111280A1 (ja) * 2018-11-30 2021-10-14 協和キリン株式会社 核酸複合体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009000926A1 (fr) * 2007-06-27 2008-12-31 Pentraxin Therapeutics Limited Combinaisons d'agents d'appauvrissement et d'anticorps anti-sap

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317120D0 (en) * 1993-08-17 1993-09-29 Royal Postgrad Med School Human serum amyloid p component
GB9711919D0 (en) 1997-06-09 1997-08-06 Ciba Geigy Ag Oligonucleotide derivatives
NZ522045A (en) 2000-03-30 2007-05-31 Whitehead Biomedical Inst RNA sequence-specific mediators of RNA interference
EP1560931B1 (fr) * 2002-11-14 2011-07-27 Dharmacon, Inc. Arnsi fonctionnel et hyperfonctionnel
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
KR20070085113A (ko) 2004-05-11 2007-08-27 가부시키가이샤 알파젠 Rna간섭을 생기게 하는 폴리뉴클레오티드, 및 이를 이용한유전자발현억제 방법
CN101111269A (zh) 2005-01-28 2008-01-23 协和发酵工业株式会社 抑制靶基因表达的组合物
CA2666185A1 (fr) 2006-10-11 2008-04-17 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Cibles de la grippe
CA2753338A1 (fr) 2008-09-22 2010-03-25 Rxi Pharmaceuticals Corporation Nanotransporteurs neutres
JP2017108502A (ja) 2015-12-08 2017-06-15 三菱自動車工業株式会社 電動機の冷却システム
WO2019100039A1 (fr) * 2017-11-20 2019-05-23 Alnylam Pharmaceuticals, Inc. Compositions d'arni de composant p amyloïde serique et leurs procédés d'utilisation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009000926A1 (fr) * 2007-06-27 2008-12-31 Pentraxin Therapeutics Limited Combinaisons d'agents d'appauvrissement et d'anticorps anti-sap

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOTTO MARINA ET AL.: "Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene", NATURE MEDICINE, NATURE PUB. CO, NEW YORK, vol. 3, no. 8, 1 August 1997 (1997-08-01), pages 855 - 859, XP002603930, ISSN: 1078-8956 *
E.C. MANTZOURANIS ET AL.: "Human serum amyloid P component. cDNA isolation, complete sequence of pre-serum amyloid P component, and localization of the gene to chromosome 1", JOURNAL OF BIOLOGICAL CHEMISTRY, 25 June 1985 (1985-06-25), United States, pages 7752 - 7756, XP055489231, Retrieved from the Internet <URL:http://www.jbc.org/content/260/12/7752.full.pdf#page=1&view=FitH> *
PEPYS M.B. ET AL.: "Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis", NATURE, MACMILLAN JOURNALS LTD, LONDON, vol. 417, no. 6886, 1 January 2002 (2002-01-01), pages 254 - 259, XP002219442, ISSN: 0028-0836, DOI: 10.1038/417254A *
See also references of WO2018221649A1 *
VINCENT MUCZYNSKI ET AL.: "Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions", BLOOD, vol. 129, no. 17, 27 April 2017 (2017-04-27), US, pages 2443 - 2454, XP055560326, ISSN: 0006-4971, DOI: 10.1182/blood-2016-06-724351 *

Also Published As

Publication number Publication date
JPWO2018221649A1 (ja) 2020-04-02
TW201903149A (zh) 2019-01-16
US20200190514A1 (en) 2020-06-18
EP3633037A1 (fr) 2020-04-08
CN110832078A (zh) 2020-02-21
WO2018221649A1 (fr) 2018-12-06
CA3065149A1 (fr) 2018-12-06
AU2018277476A1 (en) 2020-01-02
KR20200014320A (ko) 2020-02-10
US11466272B2 (en) 2022-10-11

Similar Documents

Publication Publication Date Title
AU2018289077A1 (en) Nucleic acid-guided nucleases
EP3433382A4 (fr) Spike-ins d&#39;acides nucléiques synthétiques
EP3398722A4 (fr) Dispositif d&#39;entraînement
EP3500581A4 (fr) Constructions polynucléotidiques
EP3409780A4 (fr) Complexe d&#39;acides nucléiques
EP3174980A4 (fr) Marquage d&#39;acides nucléiques pour l&#39;assemblage de séquences
EP3549722A4 (fr) Dispositif d&#39;entraînement
EP3498724A4 (fr) Complexe d&#39;acides nucléiques
EP3366773A4 (fr) Complexe d&#39;acides nucléiques
EP3410819A4 (fr) Dispositif de chauffage
EP3282814A4 (fr) Appareil chauffant
EP3405500A4 (fr) Maltosyl-isomaltooligosaccharides
EP3664576A4 (fr) Appareil de chauffage
EP3357728A4 (fr) Groupe motopropulseur
EP3471544A4 (fr) Protéines de dystrophine modifiées
EP3529400A4 (fr) Dissimulation d&#39;informations présentes dans des acides nucléiques
EP3633037A4 (fr) Acides nucléiques suppresseurs de l&#39;expression d&#39;apcs
EP3295959A4 (fr) Introduction du gène cmlck
EP3766972A4 (fr) Complexe d&#39;acide nucléique
EP3631005A4 (fr) Électrophorèse en série
EP3436582A4 (fr) Acides nucléiques de bêta-caténine et leurs utilisations
EP3618566A4 (fr) Appareil de chauffage
EP3436584A4 (fr) Acides nucléiques egfr et leurs utilisations
EP3426598A4 (fr) Caténanes de nanocommutateurs d&#39;acide nucléique
GB201609115D0 (en) Isolating nucleic acids

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210224

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/113 20100101AFI20210217BHEP

Ipc: A61K 48/00 20060101ALI20210217BHEP

Ipc: A61K 31/713 20060101ALI20210217BHEP

Ipc: A61P 3/00 20060101ALI20210217BHEP

Ipc: A61K 31/7105 20060101ALI20210217BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20231002